A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

Clinical trial NCT07086326 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07086326
Sponsor: Yang Fan, MD
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Neoadjuvant Therapy Immunotherapy AK112 Bispecific Antibody

Start date: 2025-07-31
Primary completion: 2026-12-30
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.